Tada

Thanks for that reply. The share price projection appears reasonable and attainable.

I question the per pill cost that DM has floated for this breakthru therapy - particularly when compared to the cost of Remdesivir as mentioned in the interview - I realize that it is an injection, not a pill, but the cost disparity is disproportionate. 

First things first - RVX needs to demonstrate efficacy in this trial. Once this new class of drugs gets to market there are many so-called stars behind it. 

Chicagoest